Bentley Systems and SMRT Trains Collaborate to Improve Safety and Reliability of Metro Rail Services in Singapore
Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, and SMRT Trains, the pioneer Mass Rapid Transit (MRT) operator in Singapore, have successfully completed the implementation of a Predictive Decision Support System (PDSS) for Singapore’s North-South and East-West lines, the oldest MRT lines in the country. SMRT Trains’ PDSS, which is based on Bentley’s AssetWise Linear Analytics, contributes to improving the reliability of the two lines across 282 kilometers of track and has helped SMRT Trains achieve more than 1 million kilometers between failure (MKBF). MKBF is a measure of reliability used by train operators around the world, where a failure is defined as a service delay of more than five minutes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005442/en/
Kaushik Chakraborty, vice president, Bentley Asia South, and Gan Boon Jin, president of Strides Engineering, at the MOU signing ceremony. (Photo: Business Wire)
Based on the success of the PDSS implementation on the North-South and East-West lines, SMRT Trains has started the implementation of the PDSS solution on the Circle Line (CCL) in Singapore.
With many owner-operators of large metro networks in Asia Pacific cities focusing on improving reliability to provide uninterrupted services to riders, Bentley Systems and Strides Engineering, previously SMRT Services, a business arm of SMRT Corporation that provides a range of station-based engineering services, announced the signing of a Memorandum of Understanding (MOU) to jointly market a rail predictive maintenance solution in the Asia Pacific region. The MOU establishes a partnership between the two companies that combines strong technology expertise and rail operational capabilities to help urban rail and metro operators. Under the terms of the MOU, both organizations will market a rail predictive maintenance solution that visualizes all rail asset information and manages, monitors, and analyzes rail conditions. Bentley Systems will continue to sell, implement, and support its AssetWise solution while Strides Engineering will market and deliver its domain experience and add-on applications for track maintenance.
SMRT Trains will be featured in an Infrastructure Spotlight Series webinar in November as a part of Bentley Systems’ Year in Infrastructure 2021 presentations highlighting advancements in going digital. Registration details will be available soon for this session on yii.bentley.com to learn more about how SMRT Trains is an innovator to watch.
Lam Sheau Kai, president of SMRT Trains, said, “Leveraging technology and taking pre-emptive actions are two very important components in the plan to help us improve and maintain rail reliability for the train lines SMRT Trains operates. PDSS represents both components, and its successful implementation for the North-South and East-West lines has given us much confidence to scale it for the rest of our lines.”
Commenting on the new partnership, Gan Boon Jin, president of Strides Engineering, said, “Strides Engineering’s collaboration with Bentley Systems on the PDSS demonstrates a firm partnership in combining strong domain and rail operational capabilities with proven technological expertise. The PDSS will enhance and optimize decision-making in rail maintenance. We look forward to bringing the best practices and results of PDSS to other train operators in the region.”
Kaushik Chakraborty, vice president, Bentley Asia South, said, “We are extremely happy and honored to partner with Strides Engineering to forward our common objective of advancing infrastructure. With our combined strengths and industry experience, we will empower rail and metro operators in the region to improve reliability of the infrastructure that serves citizens and residents.”
##
About SMRT Trains
SMRT Trains Ltd is the first and largest train services provider in Singapore. As a subsidiary of SMRT Corporation Ltd, we manage and operate train services on the North-South Line, East-West Line, the Circle Line, the new Thomson-East Coast Line and the Bukit Panjang Light Rail Transit.
We have set our core values to be Respect, Integrity, Service and Safety, and Excellence. SMRT Trains is committed to provide safe, reliable and comfortable service.
About Strides Engineering
Advanced Innovative Technologies & Digital Solutions
Strides Engineering, a business arm of SMRT Corporation Limited, has deep, proven experience in exploiting advanced innovative technologies as well as digital solutions and services to deliver safety, reliability, and comfort for commuters.
About Bentley Systems
Bentley Systems (Nasdaq:BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, AssetWise Linear Analytics, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005442/en/
Contact information
Press:
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems
SMRT Corporate Communications
+65 9822 0902
media@smrt.com.sg
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom